Loading…

Antidepressant effect of the translocator protein antagonist ONO-2952 on mouse behaviors under chronic social defeat stress

In preclinical models, it has been reported that social defeat stress activates microglial cells in the CNS. Translocator protein 18 kDa (TSPO) is a mitochondrial protein expressed on microglia in the CNS that has been proposed to be a useful biomarker for brain injury and inflammation. We hypothesi...

Full description

Saved in:
Bibliographic Details
Published in:Neuropharmacology 2020-01, Vol.162, p.107835, Article 107835
Main Authors: Nozaki, Kanako, Ito, Hikaru, Ohgidani, Masahiro, Yamawaki, Yosuke, Sahin, Ezgi Hatice, Kitajima, Takashi, Katsumata, Seishi, Yamawaki, Shigeto, Kato, Takahiro A., Aizawa, Hidenori
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c440t-de75341cda52a28df89697d30f3b8f4c6edaef1b6815ced53a30d95ac7698d1e3
cites cdi_FETCH-LOGICAL-c440t-de75341cda52a28df89697d30f3b8f4c6edaef1b6815ced53a30d95ac7698d1e3
container_end_page
container_issue
container_start_page 107835
container_title Neuropharmacology
container_volume 162
creator Nozaki, Kanako
Ito, Hikaru
Ohgidani, Masahiro
Yamawaki, Yosuke
Sahin, Ezgi Hatice
Kitajima, Takashi
Katsumata, Seishi
Yamawaki, Shigeto
Kato, Takahiro A.
Aizawa, Hidenori
description In preclinical models, it has been reported that social defeat stress activates microglial cells in the CNS. Translocator protein 18 kDa (TSPO) is a mitochondrial protein expressed on microglia in the CNS that has been proposed to be a useful biomarker for brain injury and inflammation. We hypothesized that a TSPO antagonist, ONO-2952, would inhibit the neuroinflammation induced by microglial hyperactivation and associated depressive-like behaviors. An in vitro analysis showed that ONO-2952 suppressed the release of pro-inflammatory cytokines and mitochondrial reactive oxygen species in cultured microglia stimulated by lipopolysaccharide. In mice submitted to chronic social defeat stress, microglia predominantly expressed TSPO in limbic areas implicated in depressive-like behaviors, including the amygdala, ventral hippocampus and nucleus accumbens, in which an increase in the production of pro-inflammatory cytokines in vivo were associated. Treating animals with ONO-2952 during chronic social defeat stress ameliorated impairments in social avoidance and anxiety-like behaviors and suppressed pro-inflammatory cytokine production, suggesting that ONO-2952 exerted an anti-stress effect in this animal model of depression. Thus, targeting TSPO as a candidate for the development of antidepressants that reduce susceptibility to chronic stress could pave the way toward therapeutic interventions for relapse prophylaxis in depression. [Display omitted] •Chronic stress induces TSPO expression in the limbic areas implicated in depression.•ONO-2952 suppresses cytokine expression induced in the limbic areas by chronic stress.•ONO-2952 inhibits cytokines and reactive oxygen species production in the cultured microglia.•ONO-2952 displays anti-anxiety and antidepressant effects.
doi_str_mv 10.1016/j.neuropharm.2019.107835
format article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1016_j_neuropharm_2019_107835</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0028390819304010</els_id><sourcerecordid>31682855</sourcerecordid><originalsourceid>FETCH-LOGICAL-c440t-de75341cda52a28df89697d30f3b8f4c6edaef1b6815ced53a30d95ac7698d1e3</originalsourceid><addsrcrecordid>eNqFkMtOAyEUhonR2Fp9BcMLTIVhmGGWtfGWGLvRNaFwcGhamABtYnx5pxkvS1cnOfn-c_kQwpTMKaH1zWbuYR9D36m4m5eEtkO7EYyfoCkVDSsaUlenaEpIKQrWEjFBFyltCCGVoOIcTRitRSk4n6LPhc_OQB8hJeUzBmtBZxwszh3gHJVP26BVDhH3MWRwHg-Yeg_epYxXL6uibHmJg8e7sE-A19Cpgwsx4b03ELHu4oBqnIJ2aosNWFAZp3zcd4nOrNomuPquM_R2f_e6fCyeVw9Py8VzoauK5MJAw1lFtVG8VKUwVrR12xhGLFsLW-kajAJL17WgXIPhTDFiWq50U7fCUGAzJMa5OoaUIljZR7dT8UNSIo8-5Ub--ZRHn3L0OUSvx2i_X-_A_AZ_BA7A7QjA8MDBQZRJO_DDHS4OIqUJ7v8tXzKGj2c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Antidepressant effect of the translocator protein antagonist ONO-2952 on mouse behaviors under chronic social defeat stress</title><source>ScienceDirect Journals</source><creator>Nozaki, Kanako ; Ito, Hikaru ; Ohgidani, Masahiro ; Yamawaki, Yosuke ; Sahin, Ezgi Hatice ; Kitajima, Takashi ; Katsumata, Seishi ; Yamawaki, Shigeto ; Kato, Takahiro A. ; Aizawa, Hidenori</creator><creatorcontrib>Nozaki, Kanako ; Ito, Hikaru ; Ohgidani, Masahiro ; Yamawaki, Yosuke ; Sahin, Ezgi Hatice ; Kitajima, Takashi ; Katsumata, Seishi ; Yamawaki, Shigeto ; Kato, Takahiro A. ; Aizawa, Hidenori</creatorcontrib><description>In preclinical models, it has been reported that social defeat stress activates microglial cells in the CNS. Translocator protein 18 kDa (TSPO) is a mitochondrial protein expressed on microglia in the CNS that has been proposed to be a useful biomarker for brain injury and inflammation. We hypothesized that a TSPO antagonist, ONO-2952, would inhibit the neuroinflammation induced by microglial hyperactivation and associated depressive-like behaviors. An in vitro analysis showed that ONO-2952 suppressed the release of pro-inflammatory cytokines and mitochondrial reactive oxygen species in cultured microglia stimulated by lipopolysaccharide. In mice submitted to chronic social defeat stress, microglia predominantly expressed TSPO in limbic areas implicated in depressive-like behaviors, including the amygdala, ventral hippocampus and nucleus accumbens, in which an increase in the production of pro-inflammatory cytokines in vivo were associated. Treating animals with ONO-2952 during chronic social defeat stress ameliorated impairments in social avoidance and anxiety-like behaviors and suppressed pro-inflammatory cytokine production, suggesting that ONO-2952 exerted an anti-stress effect in this animal model of depression. Thus, targeting TSPO as a candidate for the development of antidepressants that reduce susceptibility to chronic stress could pave the way toward therapeutic interventions for relapse prophylaxis in depression. [Display omitted] •Chronic stress induces TSPO expression in the limbic areas implicated in depression.•ONO-2952 suppresses cytokine expression induced in the limbic areas by chronic stress.•ONO-2952 inhibits cytokines and reactive oxygen species production in the cultured microglia.•ONO-2952 displays anti-anxiety and antidepressant effects.</description><identifier>ISSN: 0028-3908</identifier><identifier>EISSN: 1873-7064</identifier><identifier>DOI: 10.1016/j.neuropharm.2019.107835</identifier><identifier>PMID: 31682855</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Amygdala - drug effects ; Amygdala - metabolism ; Animals ; Antidepressive Agents - pharmacology ; Anxiety - metabolism ; Anxiety - psychology ; Avoidance Learning - drug effects ; Behavior, Animal - drug effects ; Brain - drug effects ; Brain - metabolism ; Cyclopropanes - pharmacology ; Cytokines ; Cytokines - drug effects ; Cytokines - metabolism ; Depression ; Disease Models, Animal ; Elevated Plus Maze Test ; GABA-A Receptor Antagonists - pharmacology ; Heterocyclic Compounds, 4 or More Rings - pharmacology ; Hindlimb Suspension ; Hippocampus - drug effects ; Hippocampus - metabolism ; In Vitro Techniques ; Lipopolysaccharides - toxicity ; Mice ; Microglia ; Microglia - drug effects ; Microglia - metabolism ; Nucleus Accumbens - drug effects ; Nucleus Accumbens - metabolism ; Open Field Test ; Reactive oxygen species ; Reactive Oxygen Species - metabolism ; Receptors, GABA - drug effects ; Receptors, GABA - metabolism ; Social Behavior ; Social Defeat ; Stress ; Stress, Psychological - metabolism ; Stress, Psychological - psychology ; Translocator protein</subject><ispartof>Neuropharmacology, 2020-01, Vol.162, p.107835, Article 107835</ispartof><rights>2019 Elsevier Ltd</rights><rights>Copyright © 2019 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c440t-de75341cda52a28df89697d30f3b8f4c6edaef1b6815ced53a30d95ac7698d1e3</citedby><cites>FETCH-LOGICAL-c440t-de75341cda52a28df89697d30f3b8f4c6edaef1b6815ced53a30d95ac7698d1e3</cites><orcidid>0000-0002-7247-8295 ; 0000-0001-5169-2930 ; 0000-0002-2896-1298</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31682855$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nozaki, Kanako</creatorcontrib><creatorcontrib>Ito, Hikaru</creatorcontrib><creatorcontrib>Ohgidani, Masahiro</creatorcontrib><creatorcontrib>Yamawaki, Yosuke</creatorcontrib><creatorcontrib>Sahin, Ezgi Hatice</creatorcontrib><creatorcontrib>Kitajima, Takashi</creatorcontrib><creatorcontrib>Katsumata, Seishi</creatorcontrib><creatorcontrib>Yamawaki, Shigeto</creatorcontrib><creatorcontrib>Kato, Takahiro A.</creatorcontrib><creatorcontrib>Aizawa, Hidenori</creatorcontrib><title>Antidepressant effect of the translocator protein antagonist ONO-2952 on mouse behaviors under chronic social defeat stress</title><title>Neuropharmacology</title><addtitle>Neuropharmacology</addtitle><description>In preclinical models, it has been reported that social defeat stress activates microglial cells in the CNS. Translocator protein 18 kDa (TSPO) is a mitochondrial protein expressed on microglia in the CNS that has been proposed to be a useful biomarker for brain injury and inflammation. We hypothesized that a TSPO antagonist, ONO-2952, would inhibit the neuroinflammation induced by microglial hyperactivation and associated depressive-like behaviors. An in vitro analysis showed that ONO-2952 suppressed the release of pro-inflammatory cytokines and mitochondrial reactive oxygen species in cultured microglia stimulated by lipopolysaccharide. In mice submitted to chronic social defeat stress, microglia predominantly expressed TSPO in limbic areas implicated in depressive-like behaviors, including the amygdala, ventral hippocampus and nucleus accumbens, in which an increase in the production of pro-inflammatory cytokines in vivo were associated. Treating animals with ONO-2952 during chronic social defeat stress ameliorated impairments in social avoidance and anxiety-like behaviors and suppressed pro-inflammatory cytokine production, suggesting that ONO-2952 exerted an anti-stress effect in this animal model of depression. Thus, targeting TSPO as a candidate for the development of antidepressants that reduce susceptibility to chronic stress could pave the way toward therapeutic interventions for relapse prophylaxis in depression. [Display omitted] •Chronic stress induces TSPO expression in the limbic areas implicated in depression.•ONO-2952 suppresses cytokine expression induced in the limbic areas by chronic stress.•ONO-2952 inhibits cytokines and reactive oxygen species production in the cultured microglia.•ONO-2952 displays anti-anxiety and antidepressant effects.</description><subject>Amygdala - drug effects</subject><subject>Amygdala - metabolism</subject><subject>Animals</subject><subject>Antidepressive Agents - pharmacology</subject><subject>Anxiety - metabolism</subject><subject>Anxiety - psychology</subject><subject>Avoidance Learning - drug effects</subject><subject>Behavior, Animal - drug effects</subject><subject>Brain - drug effects</subject><subject>Brain - metabolism</subject><subject>Cyclopropanes - pharmacology</subject><subject>Cytokines</subject><subject>Cytokines - drug effects</subject><subject>Cytokines - metabolism</subject><subject>Depression</subject><subject>Disease Models, Animal</subject><subject>Elevated Plus Maze Test</subject><subject>GABA-A Receptor Antagonists - pharmacology</subject><subject>Heterocyclic Compounds, 4 or More Rings - pharmacology</subject><subject>Hindlimb Suspension</subject><subject>Hippocampus - drug effects</subject><subject>Hippocampus - metabolism</subject><subject>In Vitro Techniques</subject><subject>Lipopolysaccharides - toxicity</subject><subject>Mice</subject><subject>Microglia</subject><subject>Microglia - drug effects</subject><subject>Microglia - metabolism</subject><subject>Nucleus Accumbens - drug effects</subject><subject>Nucleus Accumbens - metabolism</subject><subject>Open Field Test</subject><subject>Reactive oxygen species</subject><subject>Reactive Oxygen Species - metabolism</subject><subject>Receptors, GABA - drug effects</subject><subject>Receptors, GABA - metabolism</subject><subject>Social Behavior</subject><subject>Social Defeat</subject><subject>Stress</subject><subject>Stress, Psychological - metabolism</subject><subject>Stress, Psychological - psychology</subject><subject>Translocator protein</subject><issn>0028-3908</issn><issn>1873-7064</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNqFkMtOAyEUhonR2Fp9BcMLTIVhmGGWtfGWGLvRNaFwcGhamABtYnx5pxkvS1cnOfn-c_kQwpTMKaH1zWbuYR9D36m4m5eEtkO7EYyfoCkVDSsaUlenaEpIKQrWEjFBFyltCCGVoOIcTRitRSk4n6LPhc_OQB8hJeUzBmtBZxwszh3gHJVP26BVDhH3MWRwHg-Yeg_epYxXL6uibHmJg8e7sE-A19Cpgwsx4b03ELHu4oBqnIJ2aosNWFAZp3zcd4nOrNomuPquM_R2f_e6fCyeVw9Py8VzoauK5MJAw1lFtVG8VKUwVrR12xhGLFsLW-kajAJL17WgXIPhTDFiWq50U7fCUGAzJMa5OoaUIljZR7dT8UNSIo8-5Ub--ZRHn3L0OUSvx2i_X-_A_AZ_BA7A7QjA8MDBQZRJO_DDHS4OIqUJ7v8tXzKGj2c</recordid><startdate>20200101</startdate><enddate>20200101</enddate><creator>Nozaki, Kanako</creator><creator>Ito, Hikaru</creator><creator>Ohgidani, Masahiro</creator><creator>Yamawaki, Yosuke</creator><creator>Sahin, Ezgi Hatice</creator><creator>Kitajima, Takashi</creator><creator>Katsumata, Seishi</creator><creator>Yamawaki, Shigeto</creator><creator>Kato, Takahiro A.</creator><creator>Aizawa, Hidenori</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0002-7247-8295</orcidid><orcidid>https://orcid.org/0000-0001-5169-2930</orcidid><orcidid>https://orcid.org/0000-0002-2896-1298</orcidid></search><sort><creationdate>20200101</creationdate><title>Antidepressant effect of the translocator protein antagonist ONO-2952 on mouse behaviors under chronic social defeat stress</title><author>Nozaki, Kanako ; Ito, Hikaru ; Ohgidani, Masahiro ; Yamawaki, Yosuke ; Sahin, Ezgi Hatice ; Kitajima, Takashi ; Katsumata, Seishi ; Yamawaki, Shigeto ; Kato, Takahiro A. ; Aizawa, Hidenori</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c440t-de75341cda52a28df89697d30f3b8f4c6edaef1b6815ced53a30d95ac7698d1e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Amygdala - drug effects</topic><topic>Amygdala - metabolism</topic><topic>Animals</topic><topic>Antidepressive Agents - pharmacology</topic><topic>Anxiety - metabolism</topic><topic>Anxiety - psychology</topic><topic>Avoidance Learning - drug effects</topic><topic>Behavior, Animal - drug effects</topic><topic>Brain - drug effects</topic><topic>Brain - metabolism</topic><topic>Cyclopropanes - pharmacology</topic><topic>Cytokines</topic><topic>Cytokines - drug effects</topic><topic>Cytokines - metabolism</topic><topic>Depression</topic><topic>Disease Models, Animal</topic><topic>Elevated Plus Maze Test</topic><topic>GABA-A Receptor Antagonists - pharmacology</topic><topic>Heterocyclic Compounds, 4 or More Rings - pharmacology</topic><topic>Hindlimb Suspension</topic><topic>Hippocampus - drug effects</topic><topic>Hippocampus - metabolism</topic><topic>In Vitro Techniques</topic><topic>Lipopolysaccharides - toxicity</topic><topic>Mice</topic><topic>Microglia</topic><topic>Microglia - drug effects</topic><topic>Microglia - metabolism</topic><topic>Nucleus Accumbens - drug effects</topic><topic>Nucleus Accumbens - metabolism</topic><topic>Open Field Test</topic><topic>Reactive oxygen species</topic><topic>Reactive Oxygen Species - metabolism</topic><topic>Receptors, GABA - drug effects</topic><topic>Receptors, GABA - metabolism</topic><topic>Social Behavior</topic><topic>Social Defeat</topic><topic>Stress</topic><topic>Stress, Psychological - metabolism</topic><topic>Stress, Psychological - psychology</topic><topic>Translocator protein</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nozaki, Kanako</creatorcontrib><creatorcontrib>Ito, Hikaru</creatorcontrib><creatorcontrib>Ohgidani, Masahiro</creatorcontrib><creatorcontrib>Yamawaki, Yosuke</creatorcontrib><creatorcontrib>Sahin, Ezgi Hatice</creatorcontrib><creatorcontrib>Kitajima, Takashi</creatorcontrib><creatorcontrib>Katsumata, Seishi</creatorcontrib><creatorcontrib>Yamawaki, Shigeto</creatorcontrib><creatorcontrib>Kato, Takahiro A.</creatorcontrib><creatorcontrib>Aizawa, Hidenori</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Neuropharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nozaki, Kanako</au><au>Ito, Hikaru</au><au>Ohgidani, Masahiro</au><au>Yamawaki, Yosuke</au><au>Sahin, Ezgi Hatice</au><au>Kitajima, Takashi</au><au>Katsumata, Seishi</au><au>Yamawaki, Shigeto</au><au>Kato, Takahiro A.</au><au>Aizawa, Hidenori</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antidepressant effect of the translocator protein antagonist ONO-2952 on mouse behaviors under chronic social defeat stress</atitle><jtitle>Neuropharmacology</jtitle><addtitle>Neuropharmacology</addtitle><date>2020-01-01</date><risdate>2020</risdate><volume>162</volume><spage>107835</spage><pages>107835-</pages><artnum>107835</artnum><issn>0028-3908</issn><eissn>1873-7064</eissn><abstract>In preclinical models, it has been reported that social defeat stress activates microglial cells in the CNS. Translocator protein 18 kDa (TSPO) is a mitochondrial protein expressed on microglia in the CNS that has been proposed to be a useful biomarker for brain injury and inflammation. We hypothesized that a TSPO antagonist, ONO-2952, would inhibit the neuroinflammation induced by microglial hyperactivation and associated depressive-like behaviors. An in vitro analysis showed that ONO-2952 suppressed the release of pro-inflammatory cytokines and mitochondrial reactive oxygen species in cultured microglia stimulated by lipopolysaccharide. In mice submitted to chronic social defeat stress, microglia predominantly expressed TSPO in limbic areas implicated in depressive-like behaviors, including the amygdala, ventral hippocampus and nucleus accumbens, in which an increase in the production of pro-inflammatory cytokines in vivo were associated. Treating animals with ONO-2952 during chronic social defeat stress ameliorated impairments in social avoidance and anxiety-like behaviors and suppressed pro-inflammatory cytokine production, suggesting that ONO-2952 exerted an anti-stress effect in this animal model of depression. Thus, targeting TSPO as a candidate for the development of antidepressants that reduce susceptibility to chronic stress could pave the way toward therapeutic interventions for relapse prophylaxis in depression. [Display omitted] •Chronic stress induces TSPO expression in the limbic areas implicated in depression.•ONO-2952 suppresses cytokine expression induced in the limbic areas by chronic stress.•ONO-2952 inhibits cytokines and reactive oxygen species production in the cultured microglia.•ONO-2952 displays anti-anxiety and antidepressant effects.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>31682855</pmid><doi>10.1016/j.neuropharm.2019.107835</doi><orcidid>https://orcid.org/0000-0002-7247-8295</orcidid><orcidid>https://orcid.org/0000-0001-5169-2930</orcidid><orcidid>https://orcid.org/0000-0002-2896-1298</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0028-3908
ispartof Neuropharmacology, 2020-01, Vol.162, p.107835, Article 107835
issn 0028-3908
1873-7064
language eng
recordid cdi_crossref_primary_10_1016_j_neuropharm_2019_107835
source ScienceDirect Journals
subjects Amygdala - drug effects
Amygdala - metabolism
Animals
Antidepressive Agents - pharmacology
Anxiety - metabolism
Anxiety - psychology
Avoidance Learning - drug effects
Behavior, Animal - drug effects
Brain - drug effects
Brain - metabolism
Cyclopropanes - pharmacology
Cytokines
Cytokines - drug effects
Cytokines - metabolism
Depression
Disease Models, Animal
Elevated Plus Maze Test
GABA-A Receptor Antagonists - pharmacology
Heterocyclic Compounds, 4 or More Rings - pharmacology
Hindlimb Suspension
Hippocampus - drug effects
Hippocampus - metabolism
In Vitro Techniques
Lipopolysaccharides - toxicity
Mice
Microglia
Microglia - drug effects
Microglia - metabolism
Nucleus Accumbens - drug effects
Nucleus Accumbens - metabolism
Open Field Test
Reactive oxygen species
Reactive Oxygen Species - metabolism
Receptors, GABA - drug effects
Receptors, GABA - metabolism
Social Behavior
Social Defeat
Stress
Stress, Psychological - metabolism
Stress, Psychological - psychology
Translocator protein
title Antidepressant effect of the translocator protein antagonist ONO-2952 on mouse behaviors under chronic social defeat stress
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T10%3A41%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antidepressant%20effect%20of%20the%20translocator%20protein%20antagonist%20ONO-2952%20on%20mouse%20behaviors%20under%20chronic%20social%20defeat%20stress&rft.jtitle=Neuropharmacology&rft.au=Nozaki,%20Kanako&rft.date=2020-01-01&rft.volume=162&rft.spage=107835&rft.pages=107835-&rft.artnum=107835&rft.issn=0028-3908&rft.eissn=1873-7064&rft_id=info:doi/10.1016/j.neuropharm.2019.107835&rft_dat=%3Cpubmed_cross%3E31682855%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c440t-de75341cda52a28df89697d30f3b8f4c6edaef1b6815ced53a30d95ac7698d1e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/31682855&rfr_iscdi=true